Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis-Reference-Cited by-同舟云学术

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Published:2016-08 Issue:8 Volume:11 Page:1293-1304
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Noonan Sinéad A.,Berry Lynne,Lu Xian,Gao Dexiang,Barón Anna E.,Chesnut Patrick,Sheren Jamie,Aisner Dara L.,Merrick Dan,Doebele Robert C.,Varella-Garcia Marileila,Camidge D. Ross

Funder

University of Colorado Lung Cancer Specialized Program of Research Excellence

University of Colorado Cancer Center

Lung Cancer Mutation Consortium

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928);Planchard;Ann Oncol,2014

4. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

5. Crizotinib in ROS1-rearranged non–small-cell lung cancer;Shaw;N Engl J Med,2014

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung cancer in patients who have never smoked — an emerging disease;Nature Reviews Clinical Oncology;2024-01-09

2. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01

3. Receptor tyrosine kinases: biological functions and anticancer targeted therapy;MedComm;2023-12

4. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies;British Journal of Cancer;2023-11-08

5. Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer;Frontiers in Oncology;2023-10-20